Also Clin1b/Clin2a Alzheimer's with vascular pathology, Clin1b/Clin2a cognitive impairment in schizophrenia, Clin1 undisclosed; CY3018 Clin0 undisclosed
Cyclerion is leveraging knowledge of cyclic-GMP (cGMP) to address serious CNS diseases. Using their systems biology approach, Cyclerion has identified CNS diseases in which the NO-sGC-cGMP pathway plays a central role including both neurodegenerative and neuropsychiatric diseases. These diseases are associated with deficits in the NO-sGC-cGMP. By developing sGC stimulators, such as CY6463, Cyclerion is hoping to restore disrupted signaling while maintaining endogenous NO regulation. CY6463 is Cyclerion’s first CNS-penetrant sGC stimulator that has shown benefits in multiple animal models by improving neuronal function, reducing neuro-inflammation and enhancing cellular bioenergetics. CY6463 is now in clinical trials.